February 16, 2016 by Chain Drug Review
Burman's Specialty Pharmacy, Diplomat Pharmacy, Gary Kadlec, Paul Urick, specialty pharmacy
Leading Headlines, Pharmacy, Retail News
FLINT, Mich. — Paul Urick has been promoted to senior vice president of industry relations for pharmaceutical account management and payer strategies at Diplomat Pharmacy Inc. In his expanded role, Urick will now drive efforts in payer strategies through the development of specialty initiatives to reduce costs through patient-centered care, while also continuing to lead
August 10, 2015 by Geoff Walden and Chain Drug Review
BioRx, Burman's Specialty Pharmacy, Diplomat Pharmacy, limited-distribution drugs, Phil Hagerman, specialty pharmacy
2015, Featured Articles, Issue 08-10-2015, Issues, News
FLINT, Mich. — Diplomat Pharmacy Inc. is a growing company in a quickly growing industry. The specialty pharmacy provider has made the most of its independence, says chairman and chief executive officer Phil Hagerman, and continues to do so after last year’s initial public offering. Even though Diplomat has become publicly traded, “we absolutely still
July 6, 2015 by John Schultz and Chain Drug Review
Burman's Specialty Pharmacy, Diplomat Pharmacy, Phil Hagerman, specialty pharmacy, Steve Burman
2015, Issue 07-06-2015, Issues, News
FLINT, Mich. — Diplomat Pharmacy Inc. has acquired Burman’s Specialty Pharmacy in an $82.8 million deal. Burman’s, based in Pennsylvania, is a provider of individualized patient care with a primary focus on hepatitis C. “Burman’s shares our strong commitment to patient care,” said Diplomat chairman and chief executive officer Phil Hagerman. “We acquired Burman’s to
June 19, 2015 by Chain Drug Review and Chain Drug Review
Burman's Specialty Pharmacy, Diplomat Pharmacy, HealthTrac, hepatitis C, Phil Hagerman, Steve Burman
Business, Leading Headlines, Pharmacy, Retail News
FLINT, Mich. — Diplomat Pharmacy Inc. has purchased Burman’s Specialty Pharmacy in a deal valued at more than $82 million. Diplomat said Friday that Burman’s, located in the greater Philadelphia area, is a provider of individualized patient care with a primary focus on hepatitis C. For the 12 months ended May 31, Burman’s generated about